Sverica Capital Management has acquired a majority interest in Gener8. The investment marks Sverica’s sixth investment from its fourth fund.
Based in Sunnyvale, CA, Gener8 designs and manufactures life science instrumentation, complex clinical devices as well as advanced industrial systems, leveraging expertise in microfluidics, optics, electronics and embedded systems. Its capabilities include end-to-end design, development, prototype and low-to-medium volume manufacturing.
David Klein, founder and CEO, says: “Gener8 has independently grown to be a significant player in the technology design, engineering and manufacturing space, but in partnership with Sverica, and the associated experience and capital they bring, Gener8 will be well-positioned to realise its long-term potential as a global provider of technology solutions.”
Dave Finley, Managing Partner at Sverica, says: “Our interest in Gener8 was born out of our experience in medtech manufacturing. Gener8 occupies a compelling position at the intersection of technological trends and the commercialization of IP. Sverica is excited to partner with the Gener8 team to build a leader in the engineering and production of turnkey medical and industrial technologies.”
Gregg Osenkowski, Principal at Sverica, adds: “We were attracted to Gener8 based on their combination of broad, multidiscipline engineering competencies together with manufacturing operations, which our research showed to be a true differentiator.”
